New Data Presented on the IL-15 superagonist SO-C101 at the Society for Immunotherapy of Cancer
Updated: Feb 18, 2021
November 4, 2020 Source: Press Release
SOTIO will present three posters, including a late breaking poster on the clinical data from the ongoing Phase 1 study of IL-15 superagonist SO-C101 for the treatment of advanced solid tumors.
SOTIO, a clinical stage immuno-oncology company, and Cytune Pharma, both owned by PPF Group, today announced that they will present a late breaking poster highlighting new clinical data on SO-C101 at the Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting to be held virtually November 9-14, 2020. SO-C101 is an IL-15 superagonist currently being investigated in a Phase 1 trial for the treatment of advanced solid tumors. Two additional posters will also be presented summarizing the latest preclinical data on SO-C101.
Late breaking poster details:
Title: A multicenter open-label phase 1/1b study of SO-C101 as monotherapy and in combination with pembrolizumab in patients with selected advanced/metastatic solid tumors Poster Number: 807 Session: In-Progress Clinical Trials Presenting Author: Aurélien Marabelle, M.D., Ph.D. Date/ Time: Wednesday, November 11, from 5:15-5:45 p.m. EST and Friday, November 13 from 4:40-5:10 p.m. EST
Poster presentation details:
Title: Pharmacodynamics and pharmacokinetics of SO-C101 in cynomolgus monkeys Poster Number: 563 Session: Immune-stimulants and immune modulators Presenting Author: Irena Adkins, Ph.D. Date/ Time: Wednesday, November 11, from 5:15-5:45 p.m. EST and Friday, November 13 from 4:40-5:10 p.m. EST
Title: SO-C101 induces NK cell cytotoxicity and potentiates antibody-dependent cell cytotoxicity and anti-tumor activity Poster Number: 562 Session: Immune-stimulants and immune modulators Presenting Author: Irena Adkins, Ph.D. Date/ Time: Thursday, November 12, from 4:50-5:20 p.m. EST and Saturday, November 14 from 1:00-1:30 p.m. EST
Selected presentation materials will be made available on the SOTIO website once the presentations conclude.
Cytune Pharma is responsible for the clinical development of SO-C101 and SOTIO is a sponsor of the Phase 1 clinical trial.